Business & FinanceHealth
30 August 2021, 2:34 pm. 1 minute
Reuters reported exclusively that German genetic testing company Qiagen sees upside potential for its full-year guidance and expects a good third quarter after the company cut its forecast in July.
Finance Chief Roland Sackers told Reuters in an interview that demand for COVID-19 tests had taken yet another turn as continued breakthrough infections from the Delta coronavirus variant in some vaccinated people was fueling test kit demand.
Asked about the prospect of Qiagen becoming a takeover target again, Sackers said he had strong confidence in the group’s growth potential but would not rule out any tie-up.
The stock extended gains to hit a 21-year high after the comments, trading 2.6% higher at 47.51 versus a record 61.24 set in 2000.
Topics of Interest: Business & FinanceHealth
Type: Reuters Best
Sectors: Business & FinancePharmaceuticals & Healthcare
Win Types: Exclusivity
Story Types: Exclusive / Scoop
Media Types: Text
Customer Impact: Important Regional Story